Basel and Munich-based NUCLIDIUM AG has closed an oversubscribed CHF 26 million Series B extension, lifting its total Series B financing to CHF 105 million.
The round was led by existing investors Kurma Growth Opportunities Fund, Angelini Ventures, EIB co-investment facility Aurea, Wellington Partners, and Neva SGR, with participation from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, NRW.BANK, and other existing backers.
NUCLIDIUM is a clinical-stage radiopharmaceutical company developing copper-based radiotheranostics designed to link cancer diagnosis and treatment. The new funding will be used to advance its lead programs, NU101 and NU201, into advanced clinical trials, expand global production and manufacturing capacity, and support preclinical target development in additional solid tumor indications.
The financing underscores continued investor interest in radiopharmaceutical platforms as companies push to scale both clinical pipelines and the infrastructure needed to support them.
The round was led by existing investors Kurma Growth Opportunities Fund, Angelini Ventures, EIB co-investment facility Aurea, Wellington Partners, and Neva SGR, with participation from DeepTech & Climate Fonds, Bayern Kapital, Vives Partners, NRW.BANK, and other existing backers.
NUCLIDIUM is a clinical-stage radiopharmaceutical company developing copper-based radiotheranostics designed to link cancer diagnosis and treatment. The new funding will be used to advance its lead programs, NU101 and NU201, into advanced clinical trials, expand global production and manufacturing capacity, and support preclinical target development in additional solid tumor indications.
The financing underscores continued investor interest in radiopharmaceutical platforms as companies push to scale both clinical pipelines and the infrastructure needed to support them.